Absci (ABSI) Income from Continuing Operations (2020 - 2026)
Absci (ABSI) posted Income from Continuing Operations of 29599000.0 for Q1 2026, little changed sequentially from 29562000.0 in Q4 2025, and down 12.35% YoY from 33768468.97 in Q1 2025.
Powered by 
Analysis
Absci (ABSI) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Absci has reported Income from Continuing Operations for 7 years, with the latest figure at 29599000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 12.35% year-over-year to 29599000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 118436000.0 (down 10.2% YoY) and the FY2025 annual result came in at 115183000.0, down 11.71% from the prior year.
- Income from Continuing Operations held at 29599000.0 in Q1 2026 per ABSI's latest filing, from 29562000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 19471000.0 in Q4 2022 and troughed at 41672000.0 in Q2 2023.
- A 5-year average of 27256352.94 and a median of 27398000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations tumbled 169.62% in 2022, then jumped 40.61% in 2024.
- Over 5 years, Income from Continuing Operations stood at 19471000.0 in 2022, then retreated by 20.92% to 23545000.0 in 2023, then decreased by 23.1% to 28983000.0 in 2024, then decreased by 2.0% to 29562000.0 in 2025, then retreated by 0.13% to 29599000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 29599000.0, 29562000.0, and 28706000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Absci | 1.39 Bn | 1.19 Bn | - | -33.21 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -33.21 Mn |
| Mar 31, 2026 | -29.60 Mn |
| Dec 31, 2025 | -29.56 Mn |
| Sep 30, 2025 | -28.71 Mn |
| Jun 30, 2025 | -30.57 Mn |
| Mar 31, 2025 | -26.35 Mn |
| Dec 31, 2024 | -28.98 Mn |
| Sep 30, 2024 | -27.40 Mn |
| Jun 30, 2024 | -24.75 Mn |
| Mar 31, 2024 | -21.98 Mn |
| Dec 31, 2023 | -23.55 Mn |
| Sep 30, 2023 | -21.99 Mn |
| Jun 30, 2023 | -41.67 Mn |
| Mar 31, 2023 | -23.36 Mn |
| Dec 31, 2022 | -19.47 Mn |
| Sep 30, 2022 | -27.26 Mn |
| Jun 30, 2022 | -28.68 Mn |
| Mar 31, 2022 | -29.49 Mn |
| Dec 31, 2021 | -25.17 Mn |
| Sep 30, 2021 | -23.63 Mn |